Microsatellite instability, KRAS, BRAF, and PIK3CA gene mutations can occur in CRC and generate drug resistance, leading to a significant reduction in the effectiveness of monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) in CRC treatment (120). This evidence concerns the gene BRAF and colorectal carcinoma.